DAXOR CORP (10-Q) Summary: Period Ended September 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, and the nine-month period ended on the same date. DAXOR Corporation operates primarily in the medical technology sector, focusing on the Blood Volume Analyzer (BVA-100) and providing localized semen and blood banking services. The company's financial profile is heavily influenced by a significant portfolio of marketable securities held as "Available-For-Sale."
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2000 |
|---|---|---|
| Total Revenues | $2,011,806 | $2,174,599 |
| Operating Revenues | $464,699 | $529,208 |
| Net Income | $273,189 | $98,585 |
| Net Income Per Share | $0.06 | $0.02 |
| Cash Flow from Operations | $195,957 | ($38,213) |
| Total Assets | $43,332,092 | $49,575,118 |
| Marketable Securities (Fair Value) | $42,379,751 | $48,722,403 |
| Loans Payable | $1,968,281 | $1,775,363 |
| Shareholders' Equity | $34,561,725 | $38,671,838 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 7.5% year-over-year for the nine-month period, driven primarily by a drop in operating revenues ($464,699 vs. $529,208) and a significant reduction in realized gains on the sale of securities ($11,902 vs. $184,243).
- Profitability Increase: Despite lower revenues, Net Income increased by 176% to $273,189. This was achieved through reduced operating expenses (Laboratory operations dropped from $847,146 to $600,790) and lower net interest expenses.
- Investment Portfolio: The fair value of marketable securities declined from $48.7 million to $42.4 million. Consequently, net unrealized holding gains decreased from $26.5 million to $19.9 million, reducing the unrealized gain component of shareholders' equity.
- Liquidity: Cash and cash equivalents increased to $55,525 from $18,439 at the end of the prior fiscal year. Operating cash flow turned positive ($195,957) compared to a negative outflow in the prior year.
Outlook, Risks, and Management Commentary
- Strategic Shift: Management anticipates that sales of equipment and kits will become the major income source. However, a policy shift toward leasing or renting equipment to hospitals has slowed the recognition of operating income from BVA sales compared to direct sales in the prior year.
- Expansion Plans: The company is negotiating a distribution agreement for the Blood Volume Analyzer in Japan and evaluating options for a nationwide sales force versus independent dealer networks.
- Capital Allocation: Financial reserves are being used to develop and market the Blood Volume Analyzer. The company is also evaluating blood volume instrumentation management programs for hospitals.
- Risks: The "instrument loaner reagent plan" results in a slower return on capital expenditure. The company relies heavily on its investment portfolio for equity value, which is subject to market volatility.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the shift from direct equipment sales to leasing models and its long-term impact on cash flow timing.
- Investment Volatility: Assess the risk exposure of the $42.4 million marketable securities portfolio, which constitutes the vast majority of total assets.
- Debt Covenants: Review the terms of the $1.97 million in loans payable, which are secured by the company's marketable securities.
- Japan Expansion: Monitor the status of the potential distribution agreement in Japan as a key growth catalyst.
- Operating Margins: Confirm if the reduction in laboratory operating costs is a one-time benefit or a structural improvement.